This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

NextPaper Logo
nextpaper.ccCYBER CHRONICLE
RSS
EN中文

Full article

FULL TEXT

View this issue
Deep diveMEDTECH

Organ-on-Chip Enters Clinical Validation: Harvard Wyss Institute Achieves 92% Human Liver Function Parity

Harvard Wyss Institute's Liver-Chip demonstrated 92% functional consistency with human liver in clinical validation, capable of replacing some animal experiments for drug toxicity testing. Received FDA Breakthrough Device designation.

Organ-on-Chip Enters Clinical Validation: Harvard Wyss Institute Achieves 92% Human Liver Function Parity

On March 1, 2028, Harvard University's Wyss Institute published a paper in Science Translational Medicine announcing that its Liver-Chip demonstrated 92% functional consistency with the human liver in a large-scale clinical validation — the first time organ-on-chip technology has achieved such high organ simulation accuracy.

The Liver-Chip is a thumb-sized microfluidic chip containing hepatocytes, cholangiocytes, stellate cells, and endothelial cells differentiated from human induced pluripotent stem cells (iPSCs). These cells self-organize into micro-tissues highly similar to human liver lobule structures and maintain function for up to 6 weeks under continuous medium perfusion.

Technical Principles

Wyss Institute founder Professor Don Ingber stated: 'Traditional cell culture occurs on flat surfaces where cells lack the authentic 3D microenvironment and blood flow shear forces. Our chip simulates hepatic sinusoidal blood flow through microfluidic channels and mimics respiratory motion through periodic mechanical stretching — these physical signals are crucial for maintaining liver function.'

The chip integrates 36 micro-sensors that continuously monitor oxygen partial pressure, pH, glucose consumption, lactate production, and albumin secretion. This data feeds into a machine learning model that predicts drug metabolic pathways and toxicity responses in humans.

Validation Results

In collaboration with Pfizer, Roche, and Johnson & Johnson, the Wyss Institute tested 87 drugs with known metabolic and toxicity profiles on the Liver-Chip:

  • Drug metabolic pathway prediction accuracy: 94%
  • Hepatotoxicity prediction sensitivity: 89% (vs. 52% for traditional animal experiments)
  • False positive rate: only 7%

FDA has granted the Liver-Chip Breakthrough Device designation, providing an accelerated approval pathway. FDA Commissioner Robert Califf stated: 'Organ-on-chip technology has the potential to transform the drug development paradigm — faster, more accurate, and more humane.'

Industry Impact

In drug development, animal experiments have a 90% failure rate — drugs safe and effective in animals fail in human trials 90% of the time. Organ-on-chip technology is seen as the key solution.

Charles River Laboratories, a global drug development outsourcing giant, has announced an exclusive partnership with the Wyss Institute to deploy Liver-Chips across its 40 laboratories worldwide. The company's CEO said: 'We expect Liver-Chips to replace at least 30% of animal hepatotoxicity experiments within three years.'

Ethical Significance

The organ-on-chip's other major significance lies in reducing animal experimentation. Approximately 100 million animals are used in experiments globally each year. Humane Society International stated: 'The Liver-Chip's 92% human consistency means we no longer need animals to predict human liver reactions — this is an ethical milestone.'